Headlines about Mesoblast Limited (NASDAQ:MESO) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast Limited earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.4731036313431 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s analysis:
Mesoblast Limited (NASDAQ MESO) traded down 0.273% during mid-day trading on Friday, reaching $5.485. The company had a trading volume of 19,937 shares. Mesoblast Limited has a 52 week low of $4.01 and a 52 week high of $12.50. The stock has a 50 day moving average of $6.06 and a 200 day moving average of $7.78. The stock’s market capitalization is $465.92 million.
Several equities research analysts recently issued reports on MESO shares. BidaskClub lowered shares of Mesoblast Limited from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Maxim Group set a $14.00 price target on Mesoblast Limited and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Oppenheimer Holdings, Inc. started coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price target for the company. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price target on shares of Mesoblast Limited in a research note on Wednesday, August 30th. Finally, ValuEngine downgraded Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.14.
ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/mesoblast-limited-meso-earning-somewhat-positive-news-coverage-study-finds.html.
Mesoblast Limited Company Profile
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.